StockIQpro
NASDAQ:COCP

Cocrystal Pharma, Inc.

Track all markets on TradingView
Track all markets on TradingView

Cocrystal Pharma, Inc. reported net income of −$8.8M in fiscal 2025. Free cash flow was −$8.2M, and the diluted share count rose 11.0%.Summary generated from Cocrystal Pharma, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−111.4%
Debt / equityn/a
Free cash flow−$8.2M
FCF marginn/a
Share count change+11.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−14−39−19−18−9
Net income−14−39−18−18−9
Free cash flow−13−22−15−16−8

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations